GlassScriptPhysician profile
Bryan W Davis
NPI 1295760080
$2,805.34
in general payments reported to CMS, 2019-2025
30 companies · $767 in 2025
The $767 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $438 · 2021: $129 · 2022: $204 · 2023: $355 · 2024: $496 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,617.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $510.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $435.97 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $276.90 | 2019-2025 | Farxiga, Breztri |
| Amgen INC. | $207.00 | 2019-2025 | Repatha, Otezla, Repatha |
| Allergan, INC. | $147.39 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.12 | 2020-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $109.77 | 2019-2021 | |
| Pfizer INC. | $108.18 | 2020-2025 | |
| Abbvie INC. | $101.25 | 2022-2025 | Qulipta |
| Esperion Therapeutics, INC. | $80.02 | 2024-2025 | Nexletol |
| Arbor Pharmaceuticals, INC. | $79.54 | 2019-2021 | |
| Radius Health, INC. | $72.20 | 2020-2024 | Tymlos |
| Dexcom, INC. | $68.47 | 2024-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $58.39 | 2025 | Eterna, Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $58.29 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $39.90 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.78 | 2022 | |
| Tolmar, INC. | $35.18 | 2024-2025 | Jatenzo |
| Antares Pharma, INC. | $34.11 | 2024-2025 | Xyosted |
| Exact Sciences Corporation | $31.56 | 2025 | The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $28.76 | 2023 | Arexvy, Shingrix |
| Jazz Pharmaceuticals INC. | $28.37 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.10 | 2022 | |
| Ironshore Pharmaceuticals INC. | $18.41 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.84 | 2019 | |
| Supernus Pharmaceuticals, INC. | $16.76 | 2022 | Xyosted, Tlando |
| Kowa Pharmaceuticals America, INC. | $15.40 | 2020 | |
| Azurity Pharmaceuticals, INC. | $15.35 | 2022 | |
| Strongbridge US INC. | $13.90 | 2020 | |
| Halozyme INC | $13.74 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.